Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
Sari D. Hopson, PhD, MSPH
Advertisement
Articles by Sari D. Hopson, PhD, MSPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
2
Fifth Death Confirmed in NYC Legionnaires' Outbreak
3
FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC
4
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
5